Syros Pharmaceuticals /zigman2/quotes/201168308/composite SYRS -0.44% said in a filing Monday that it expects its initial public offering of stock to price between $14 and $16 a share. The biopharmaceutical company, which has developed a gene-control platform, said it will offer 4 million common shares for sale in its IPO, to raise up to $64 million, before fees. Including options granted to the underwriters to purchase additional shares, the company could raise up to $73.6 million, before fees. The company expects the proceeds from the IPO to be sufficient to enable it to reach clinical activity data readouts its SY-1425 product candidate for treating acute myelogenous leukemia and myelodysplastic syndrome, and its SY-1365 candidate for treating acute leukemias. The company plans to list the stock on Nasdaq under the symbol "SYRS."